不可逆电穿孔局灶治疗局限性肾细胞癌的初步疗效评估:IRENE试验
IRENE是一项前瞻性单中心2a期先消融后切除 pilot 研究,评估经皮CT引导下不可逆电穿孔(IRE)消融pTa1a肾细胞癌(RCC)的疗效。
要点
- 经皮IRE消融pT1a RCC技术可行且安全,无重大并发症。
- 术后4周病理显示7例中4例完全消融,3例微观不完全消融。
- IRE操作复杂,平均手术时间129分钟,需技术改进以提高完全消融率。
核心结论
- 肾经皮IRE似乎是pT1a RCC的安全治疗方法,但需要大量操作努力。
- 消融区域切除标本显示IRE后4周微观不完全消融率高。
- 根据这些初步结果,T1a RCC的治愈性保肾消融似乎可行,但需要技术改进以确保完全消融。
研究设计与样本
- 前瞻性单中心2a期先消融后切除 pilot 研究(IRENE试验)。
- 纳入前7例活检证实的pT1a RCC患者,肿瘤大小15-39 mm。
主要发现
- 所有患者技术可行性均达成,但电极放置和消融复杂,平均总手术时间129分钟。
- 无重大并发症。
- 5例患者行部分肾切除术,2例因中央肿瘤位置和消融区域行根治性肾切除术。
- 切除标本按UICC 2017 TNM分类:4例完全消融(ypT0V0N0Pn0R0),3例微观残留肿瘤细胞为不完全消融(ypT1aV0N0Pn0R1)。
临床怎么用
- 对于pT1a RCC,经皮IRE可作为保肾消融的潜在选择,但需认识到当前技术下不完全消融风险较高。
- 操作复杂且耗时,需由经验丰富的团队实施,并考虑技术改进以提高完全消融率。
局限性
- 样本量小(仅7例),为初步 pilot 研究。
- 单中心设计,结果需进一步验证。
- 缺乏长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of irreversible electroporation (IRE) ablation of pT1a renal cell carcinoma (RCC) in the first prospective, monocentric phase 2a pilot ablate-and-resect study (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] trial). It has been postulated that focal IRE can bring about complete ablation of soft-tissue tumors with protection of healthy peritumoral tissue and anatomic structures. PATIENTS AND METHODS: The first 7 study patients with biopsy-proven pT1a RCC (15-39 mm) underwent IRE. Percutaneous computed tomography-guided IRE was performed with electrocardiographic triggering under general anesthesia and deep muscle paralysis with 3-6 monopolar electrodes positioned within the renal tumor. Twenty-eight days later, the tumor region was completely resected to confirm tumor destruction pathologically. Individual results for these patients are displayed, described, and discussed. RESULTS: Technical feasibility was attained in all patients, but electrode placement and ablation were complex, with a mean overall procedure time of 129 minutes. There were no major complications. Partial kidney resection was performed in 5 patients, and radical nephrectomy was performed in 2 patients because of central tumor location and ablation areas. Resections revealed by tumor, node, and metastasis classification of the International Union for Cancer Control 2017 no residual tumor as complete ablation in 4 cases (ypT0V0N0Pn0R0) and microscopic residual tumor cells as incomplete ablation in the other 3 cases (ypT1aV0N0Pn0R1). CONCLUSION: Renal percutaneous IRE appears to be a safe treatment for pT1a RCC but requires substantial procedural effort. Resection specimens of the ablation zone revealed a high rate of microscopic incomplete ablation 4 weeks after IRE. According to these initial study results, curative, kidney-sparing ablation of T1a RCC appears possible but needs technical improvement to ensure complete ablation.
引用
- Wendler JJ, Pech M, Fischbach F, et al. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study). Urology. 2018. PMID: 29305201. doi:10.1016/j.urology.2017.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。